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Objective: Disturbances of the alveolar surfactant system have been implicated in
the pathogenesis of reperfusion injury. The aim of this study was to evaluate the
influence of exogenous surfactant administration on surfactant properties in a model
of single lung transplantation.
Methods: We performed heterologous, left lung transplantation (4°C ischemia; 24
hours, Euro-Collins solution) in 6 foxhounds (untreated) and in 6 animals that
received calf lung surfactant extract (Alveofact) prior to explantation (only donor
lung; 50 mg/kg body weight) and immediately after onset of reperfusion (both
lungs, 200 mg/kg body weight). Separate but synchronized ventilation of each lung
was performed, in a volume-controlled, pressure-limited mode, with animals in
prone position. Bronchoalveolar lavage fluids were collected in pretransplantation
lungs (control), after 24 hours of ischemia prior to transplantation (0 hours) and 6
and 12 hours after reperfusion in both the grafts and the recipient native lungs.
Results: Ischemic storage per se did not provoke any changes of the surfactant
system; however, severe alterations occurred within 6 hours of reperfusion, resulting
in a severe loss of surface activity, including a decrease in the percentage of the
large surfactant aggregate fraction, reduction of the surfactant apoproteins SP-B and
SP-C, the dipalmitoyl molecular species of phosphatidylcholine and phosphatidyl-
glycerol within the large surfactant aggregate fraction. These abnormalities were
restricted to the graft, with virtually normal surfactant function and composition
being found in the recipient native lung. Surfactant administration fully normalized
the biochemical and largely improved the biophysical surfactant properties, along-
side maintenance of lung gas exchange properties.
Conclusions: Severe surfactant abnormalities occur exclusively in the graft when
performing separate, synchronized ventilation of each lung to attenuate ventilator-
induced lung injury. Bronchoscopic surfactant administration provides protection
against these abnormalities and may be a therapeutic strategy in lung transplantation.
Pulmonary surfactant is a highly surface-active lipoprotein complexcovering the alveoli of the lung. The major constituents of thismaterial are phospholipids (approximately 80% phosphatidylcholine(PC) and 10% phosphatidylglycerol) and the surfactant apoproteins(SP)-A, SP-B, SP-C, and SP-D.1 Both surfactant lipids and apopro-teins act in concert to facilitate rapid surfactant adsorption to the
air–liquid interface and to reduce the alveolar surface tension to near zero values at
end-expiration.2 Dipalmitoyl-phosphatidylcholine (DPPC), phosphatidylglycerol,
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SP-B, and SP-C were found to be particularly relevant in
this context. By this far-reaching reduction of surface ten-
sion, stabilization of alveoli is enabled, thereby keeping
shunt flow at low numbers. An intact surfactant system is
thus a prerequisite for breathing at normal transpulmonary
pressures and ascertains highly efficient gas exchange. Ac-
cordingly, surfactant abnormalities have been encountered
in different states of acute respiratory distress including
classic acute respiratory distress syndrome (ARDS) trig-
gered by systemic inflammatory events3 and severe pneu-
monia necessitating mechanical ventilation,4 and transbron-
chial surfactant administration was recently shown to
acutely improve gas exchange and to reduce pulmonary
shunt flow in patients with ARDS.5-7
Reperfusion injury is a frequent complication of lung
transplantation, representing a major threat to these patients.
Although the mechanisms underlying this clinical condition
are not precisely known, surfactant alterations might be well
operative as many of the inflammatory events observed
under conditions of reperfusion injury resemble those in
ARDS.8 Accordingly, the potential use of an exogenous
surfactant therapy in lung transplantation was suggested 10
years ago.9 Ultrastructural analysis of surfactant after ex-
perimental ischemia-reperfusion injury revealed a signifi-
cant reduction in the biophysically active tubular myelin
and a corresponding increase in the less active unilamellar
surfactant components.10 In addition, in experimental stud-
ies of lung transplantation in dogs, including varying isch-
emia times (6-38 hours),11-14 surfactant abnormalities were
noted and included altered phospholipid profiles, reduced
content of SP-A, decreased relative amounts of large sur-
factant aggregates, and loss of surface activity. However, no
detailed analysis of the fatty acid composition and the
molecular species of PC was hitherto performed, and data
on the hydrophobic surfactant apoprotein SP-C and on the
influence of plasma protein leakage in posttransplantation
lungs are currently not available. We therefore analyzed
biochemical and biophysical surfactant changes in canine
lungs undergoing 24 hours of cold ischemia and 12 hours of
reperfusion to explore the impact of bronchoscopic surfac-
tant administration.
Methods
Materials
A calf lung surfactant extract (Alveofact), consisting of phospho-
lipids, neutral lipids, and the 2 hydrophobic surfactant proteins
SP-B and SP-C,15 was kindly given to us by Dr H. Weller (Tho-
mae, Biberach, Germany). A monoclonal antibody against SP-B
(8B5E) and a polyclonal antibody against SP-C were kindly pro-
vided by Dr Y. Suzuki (Chest Disease Research Institute, Kyoto,
Japan) and Dr W. Steinhilber (Altana Pharm, Konstanz, Germany),
respectively.
Transplantation Model
Details of the transplantation procedure and of the ventilator
settings are given in the companion article.15a In summary, the
dogs (12 donors, 12 recipients, both sexes, 27-33 kg, weight-
matched, all receiving humane care in accordance with the Guide
for the Care and Use of Laboratory Animals [National Academies
Press, Washington, DC, 1996]) were randomly assigned to either
the control group (6 donors, 6 recipients) or the surfactant treat-
ment group (6 donors, 6 recipients). Donors underwent left lateral
thoracotomy. In the surfactant group, 50 mg/kg body weight (BW)
Alveofact was instilled bronchoscopically in 10 divided doses
stepwise into each segment of the left lung. No transbronchial fluid
application was performed in the control group. Lungs were then
perfused with 60 mL/kg of 4°C cold, modified Euro-Collins solu-
tion (including 100 g/L prostaglandin E2 [PGE2]). The lungs
were inflated to a pressure of 20 cm H2O, the trachea was stapled,
and the heart-lung block was stored at 4°C for 24 hours. Recipients
also underwent left lateral thoracotomy. The left lung was
clamped, excised and lavaged ex situ (“baseline”). The donor left
lung was implanted subsequently. The preserved and stored but
nontransplanted right donor lung was lavaged ex situ to assess
storage-induced changes (“postischemia”). The transplanted left
lung and the native right lung of the recipient were then ventilated
separately but synchronized in a master and slave modus in a
volume-controlled, pressure-limited fashion. Upon ventilation of
the donor lung, reperfusion was started and time was set to zero. In
the surfactant group, a second dose (200 mg/kg BW) of Alveofact
was administered bronchoscopically into both lungs at divided
doses, directly upon onset of reperfusion and positioning of the
animals in the prone position. No application of fluids was per-
formed in the control group.
Bronchoalveolar Lavage Technique
All lavages (baseline, postischemia, and native lung and graft
postreperfusion) were performed ex vivo except for the broncho-
scopically performed lavage 6 hours postreperfusion. In case of ex
vivo lavage, the main bronchus of the lower lobe was cannulated
and fixed by a transbronchial suture, and 500 mL of sterile saline
solution was carefully instilled and reaspirated 3 times by a passive
pressure gradient of 40 cm H2O. The overall fluid recovery was
79.2%  4.9% (mean  standard error of the mean [SEM]). The
6-hour postreperfusion lavages were obtained by placing the bron-
choscope in wedge position into a segment bronchus of the left and
right upper lobe and by lavaging this segment with 10  20 mL of
sterile saline solution, with a fluid recovery of 69.2%  2.3%
(mean  SEM). The fractions were pooled, filtered through sterile
gauze, and centrifuged at 200g (10 minutes, 4°C).
Surfactant Analysis
Lipid extraction, quantification of total phospholipid and protein
concentrations, and characterization of phospholipid profiles
(high-performance thin-layer chromatography) were performed as
recently published.4 PC fatty acids and plasmalogens (alkenyl-
acyl-PC) were determined using gas chromatography as previously
described.16,17 The ratio of the detected dimethylacetals to fatty
acid methyl esters indicated the relative amount of plasmalogens
within the PC fraction. The profile of molecular species of PC was
analyzed following phospholipolytic cleavage of the polar head
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group with phospholipase C and conversion of the resulting dira-
dylglyceroles with 1-naphthylisocyanate by means of high-perfor-
mance liquid chromatography following a variation of the method
described by Ruestow and colleagues.18 SP-B and SP-C were
quantified using recently described enzyme-linked immunosorbent
assay techniques,19,20 with isolated canine SP-B and SP-C21 serv-
ing as standard. For characterization of relative content of large
surfactant aggregates (LSA) and surface activity, bronchoalveolar
lavage fluid (BALF) was centrifuged at 48,000g (1 hour, 4°C), the
pellet was resuspended in a small volume of 0.9% NaCl containing
3 mmol/L CaCl2 and assessed for the phospholipid (PL) content.
Recovery of PL in the pellet (LSA) was used to calculate relative
LSA content. Surface activity of the LSA fraction, adjusted to 2
mg/mL PL always, was determined using a pulsating bubble
surfactometer (Electronetics, New York, NY) as previously de-
scribed.4,22 The surface tension after 5 minutes of film oscillation
and at minimum bubble radius (min) is given. If possible, the
LSA preparations were recombined with purified BALF proteins
and reanalyzed for surface activity as outlined previously.4
Statistics
All results are given as mean  SEM and were analyzed by a
biostatistician (Moredata GmbH, Giessen, Germany). Statistical
analysis of differences between surfactant-treated lungs and con-
trols was performed by testing principle significant diversity first
(Kruskal-Wallis H-test), followed by comparison with a nonpa-
rameteric test (Mann-Whitney U test). A Wilcoxon matched-pair
test was used to compare baseline values with each time point.
Results
Ischemic storage of the donor lungs did not evoke a signif-
icant influx of plasma proteins or cells into the alveolar
compartment. After reperfusion, however, a marked inflam-
matory response was encountered in both the graft and the
native organ, with markedly increased permeability, pro-
nounced neutrophil influx, and increased alveolar protein
levels. As a result, lung compliance and gas exchange of the
graft, and in the further course also of the native lung,
progressively deteriorated (see companion paper15a).
Concerning the surfactant properties, ischemic storage of
the lungs per se did not evoke any significant change in the
surfactant composition. In detail, unchanged concentrations
of total phospholipids, phospholipid/protein ratio, and rela-
tive amount of large surfactant aggregates (LSA; all Table 1)
were observed. Moreover, phospholipid-profiles (Table 2)
and the pattern of molecular species of PC (Figure 1 and
Table 4) in the lungs undergoing ischemic storage largely
corresponded to the findings under baseline conditions.
Similarly, relative content of palmitic acid and plasmalo-
gens in PC were unaltered after 24 hours of cold ischemic
storage (Table 2). The relative amount of the 2 hydrophobic
surfactant apoproteins SP-B and SP-C within the LSA frac-
tion was found to range from 1.1% (SP-B; wt/wt of total
PL) to 0.5% (SP-C) and did not change upon ischemic
TABLE 1. Phospholipid content of BALF, relative content of LSA and phospholipid/protein ratio
Baseline
0 hours post
ischemia
6 hours post
reperfusion
12 hours post
reperfusion
Phospholipid (g/mL)
Standard treatment
Donor lung 264.0 33.6 R 71.9 23.5 L 146.7 12.8 L
Native lung 158.2 20.3 52.2 10.9 137.9 42.2
Surfactant treatment
Donor lung 182.2 50.2 R 499.0 75.5 L* 857.5 202.6 L†
Native lung 158.2 35.3 418.9 169.0 539.6 69.1*
Phospholipid/protein ratio
Standard treatment
Donor lung 0.58 0.05 R 0.11 0.02 L 0.22 0.15 L
Native lung 0.70 0.07 0.39 0.08 0.28 0.07
Surfactant treatment
Donor lung 0.53 0.10 R 1.11 0.41 L† 0.56 0.11 L
Native lung 0.59 0.16 2.20 0.63† 1.50 0.26‡
LSA (in % of total PL)
Standard treatment
Donor lung 85.0 4.2 R 29.7 9.0 L 65.1 12.7 L
Native lung 94.4 3.2 70.1 4.4 76.2 13.2
Surfactant treatment
Donor lung 71.9 10.3 R 81.2 8.6 L‡ 82.5 7.9 L
Native lung 82.5 5.3 87.3 6.5† 85.7 3.9
BALF, Bronchoalveolar lavage fluid; LSA, large surfactant aggregates; PL, phospholipids; R, right donor lung after ischemia; L, transplanted graft (left donor
lung).
Given are the phospholipid concentration of BALF, the phospholipid/protein ration, and the relative amount of large surfactant aggregates (in % of total
PL) for the donor lung and the native lung in the standard treatment and the surfactant-treated group. Baseline  explanted left recipient lung. Mean 
SEM of 6 independent experiments is given.
*P  .001, †P  .05, ‡P  .01, comparison between untreated and treated organs.
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storage (Table 3). In accordance, the minimum surface
tension (min) was consistently found to range below 5
mN/m in these samples (Figure 2).
In contrast, transplantation of the graft and reperfusion
over 12 hours resulted in far-reaching alterations of the
surfactant system. The total concentration of phospholipids
was reduced in the 6-hour BALF obtained by bronchos-
copy, as was the relative amount of LSA (Table 1). Due to
the markedly increased alveolar protein values, the phos-
pholipid/protein ratio was decreased by nearly 1 order of
TABLE 2. Phospholipid profile and relative content of palmitic acid and plasmalogens in phosphatidylcholine
Baseline
0 hours post
ischemia
6 hours post
reperfusion
12 hours post
reperfusion
Phosphatidylcholine
Standard treatment
Donor lung 85.9 1.8 R 85.1 1.9 L 86.0 1.4 L
Native lung 84.6 2.5 84.7 3.0 83.8 1.3
Surfactant treatment
Donor lung 82.6 2.2 R 85.5 1.6 L 86.9 1.6 L
Native lung 82.3 1.8 85.9 1.8 85.5 1.7
Phosphatidylglycerol
Standard treatment
Donor lung 9.9 1.5 R 7.7 1.1 L 6.4 1.1 L
Native lung 10.4 1.9 9.1 1.7 10.8 1.6
Surfactant treatment
Donor lung 12.7 1.6 R 9.5 1.1 L 9.8 1.5 L*
Native lung 11.8 0.9 10.0 1.1 9.1 1.6
Phosphatidylinositol
Standard treatment
Donor lung 1.3 0.2 R 2.0 1.0 L 2.2 1.0 L
Native lung 1.7 0.2 1.9 0.4 1.2 0.2
Surfactant treatment
Donor lung 1.3 0.3 R 1.3 0.5 L 0.5 0.1 L*
Native lung 1.6 0.6 1.0 0.1 0.6 0.1*
Sphingomyelin
Standard treatment
Donor lung 2.1 0.6 R 3.9 0.6 L 2.7 0.6 L
Native lung 2.1 0.7 1.6 0.4 1.7 0.4
Surfactant treatment
Donor lung 1.8 0.3 R 1.6 0.4 L 1.4 0.2 L*
Native lung 1.6 0.6 1.4 0.4 2.1 0.7
16:0 (% of PC)
Standard treatment
Donor lung 64.9 0.5 R 46.8 4.2 L 49.2 3.6 L
Native lung 63.6 1.1 59.9 3.1 60.7 2.7
Surfactant treatment
Donor lung 65.3 0.9 R 61.0 2.9 L* 63.8 1.0 L†
Native lung 65.0 0.6 64.3 0.5 64.0 0.8
Plasmalogens (% of PC)
Standard treatment
Donor lung 4.1 0.2 R 5.2 1.2 L 5.0 0.9 L
Native lung 3.9 0.3 5.1 0.7 4.6 0.7
Surfactant treatment
Donor lung 3.6 0.2 R 5.8 0.3 L 5.9 0.1 L
Native lung 3.6 0.3 5.3 0.5 5.6 0.2
PC, Phosphotidylcholine; PL, phospholipids; R, right donor lung after ischemia; L, transplanted graft (left donor lung).
Given are the relative concentrations of PC, phosphatidylglycerol, phosphatidylinositol, and sphingomyelin (in % of total PL), the relative content of palmitic
acid (16:0) in percent (w/w) of all phosphatidylcholine fatty acids, and the relative content of plasmalogens in PC for the donor lung and the native lung
in the standard treatment and the surfactant-treated group. Phospholipids with a relative distribution lower than 1.0% under baseline conditions
(lysophosphatidylcholine, cardiolipin, phosphatidylethanolamine, phosphatidylserine) are not given. The mean  SEM of 6 independent experiments is
given.
*P  .05, †P  .01, comparison between untreated and treated organs.
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magnitude (Table 1). The relative amount of SP-B and SP-C
within the LSA fraction was found to be reduced by 50%
within 6 hours after reperfusion (Table 3). At 12 hours after
onset of reperfusion, some of these changes had partially
resolved (PL, LSA, SP-C, SP-B).
Concerning the phospholipid profile, only minor changes
were encountered upon reperfusion of the ischemic lungs,
including a significant reduction in phosphatidylglycerol
and a small increase in phosphatidylinositol and sphingo-
myelin (Table 2). Although the relative concentration of PC
did not change over the entire reperfusion period, profound
alterations of the fatty acid and molecular species profile of
PC were observed, with a marked decline in the degree of
palmitoylation of this phospholipid (see Figure 1 and Tables
2 and 4). In detail, the percentage of palmitic acid within the
PC class was reduced from 65% under baseline conditions
to 50% after 12 hours of reperfusion (P  .001, Table 2).
Concomitantly, unsaturated PC species, mostly oleic acid
(18:2) and arachidonic acid (20:4), were increased (data not
shown). These changes were even more prominent for the
dipalmitoylated PC (DPPC, Figure 1 and Table 4): the
relative amount of DPPC (given as % of total PC) was
reduced from 44% under baseline conditions to 30% after
6 hours (P .001) and maintained at this low level over the
rest of the reperfusion period. Instead, 16:0/18:1, 16:0/18:2,
16:0/20:4, and 16:0/trans18:1 species increased and entirely
compensated for this loss of DPPC. As a result, the absolute
DPPC quantities in the lavage fluid, reflecting changes in
the molecular species profile as well as total changes of PL
and PC concentrations, were reduced by 50% (Figure 1).
The relative concentrations of PC plasmalogens slightly
increased during the reperfusion period (see Table 2).
The surface activity of LSA from the graft progressively
deteriorated during reperfusion. The minimum surface ten-
sion (min) increased from 2 mN/m at baseline in isch-
emic but nonperfused lungs to 15 mN/m after 6 hours and
to 16 mN/m after 12 hours of reperfusion (Figure 2, left
panel). In addition, a further increase in the min values
was encountered upon reconstitution of the LSA fraction
with the isolated and concentrated supernatant proteins orig-
inating from the same lavage (reconstitution performed at
the same ratio as observed in original BALF): min values
then increased from 3 mN/m (baseline) to 21 mN/m after
6 hours and 26 mN/m after 12 hours of reperfusion
(Figure 2, right panel). Reductions in PC palmitic acid
content were significantly correlated with the increase in
Figure 1. Relative amount (in percent of all phosphatidylcholine molecular species, left panel) and absolute
concentration (right panel) of dipalmitoylated phosphatidylcholine (DPPC) molecular species from BALF of treated
and untreated grafts and native lungs during reperfusion over 12 hours. Depicted are the mean  SEM of 6
independent experiments. *P < .05, **P < .01, comparison between untreated and treated organs. The 0-hour
values of the native lung represent the baseline values (excised lung from the recipient) and the 0-hour values of
the graft represent the postischemia values (obtained by bronchoalveolar lavage [BAL] of the nontransplanted lung
at the end of the ischemia period).
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minimum surface tension in LSA of non–surfactant-treated
animals (Figure 3).
In contrast to the transplanted lung, the native lung
displayed, at best, minor alterations of surfactant character-
istics. There was, for example, a slight but nonsignificant
increase in the minimum surface tension at 6 and 12 hours.
The phospholipid profile, the fatty acid profile, and the
molecular species pattern of PC, as well as the concentra-
tions of SP-B and SP-C, remained within the normal range
in the native lungs of the animals receiving a contralateral
graft (Tables 1 to 4, Figures 1 and 2).
Transbronchial application of 50 mg/kg BW of a calf
lung surfactant extract (Alveofact) only into the donor lung
prior to ischemia and of another 200 mg/kg BW into both
lungs directly after onset of reperfusion resulted in a pro-
nounced improvement of gas exchange and lung compli-
ance (data not shown), which was accompanied by a far-
reaching restoration of the biochemical and biophysical
surfactant properties. In parallel to a marked increase in the
total BALF phospholipid content, reflecting the alveolar
deposition of the exogenous surfactant, a normalization of
the phospholipid/protein ratio and the relative amount of
LSA (Table 1) was noted. The relative content of PC
palmitic acid (Table 2), the molecular species profiles (Fig-
ure 1 and Table 4), and the relative content of the hydro-
phobic apoproteins in the LSA fraction (Table 3) in lungs
post–surfactant administration approached those measured
in the exogenous surfactant material (data not given in
detail). The surface activity was largely improved (Figure
2): min values of LSA originating from the graft at the end
of the reperfusion period were 5 mN/m after surfactant
therapy, as compared with16 mN/m in the absence of this
intervention (Figure 2, left). In addition, due to the far-
reaching restoration of physiological phospholipid/protein
ratios, the additional impact of protein inhibition was far
less pronounced, with graft min values measuring  15
mN/m instead of 26 mN/m after 12 hours of reperfusion
(Figure 2, right).
Discussion
As outlined in detail in the accompanying article,15a trans-
plantation and reperfusion of canine lungs that had been
stored for 24 hours at 4°C provoked a severe reperfusion
injury, with increased endothelial and epithelial permeabil-
ity, plasma protein leakage into the alveolar space, in-
creased neutrophil influx into this compartment, progressive
deterioration of gas exchange, and loss of lung compliance.
We show here that, in parallel, severe disturbances of the
surfactant system are encountered, with loss of adsorption
facilities and minimal surface tension–lowering properties.
As with the physiological abnormalities, these surfactant
alterations were largely restricted to the transplanted lung
and were obvious within 6 hours of reperfusion. Lung
storage at 4°C itself did not provoke substantial changes of
the surfactant system. The transbronchial administration of
overall 250 mg/kg BW calf lung surfactant extract normal-
ized biochemical surfactant properties and nearly fully re-
stored physiological surfactant function and at the same
time prevented the loss of gas exchange properties and
compliance of the transplanted lung.
The present study spent particular effort in the detailed
analysis of the surfactant abnormalities occurring in the
TABLE 3. Concentration of SP-B and SP-C in large surfactant aggregates
Baseline
0 hours post
ischemia
6 hours post
reperfusion
12 hours post
reperfusion
SP-B (% of PL)
Standard treatment
Donor lung 1.22 0.30 R 0.58 0.12 L 1.06 0.34 L
Native lung 1.02 0.17 0.97 0.21 0.90 0.23
Surfactant treatment
Donor lung 1.24 0.27 R 1.30 0.25 L* 1.84 0.55 L
Native lung 1.17 0.30 1.53 0.21 1.65 0.07*
SP-C (% of PL)
Standard treatment
Donor lung 0.72 0.21 R 0.15 0.19 L 0.29 0.15 L
Native lung 0.52 0.09 0.33 0.15 0.82 0.31
Surfactant treatment
Donor lung 0.69 0.09 R 1.29 0.17 L* 1.88 0.25 L†
Native lung 0.42 0.05 0.82 0.10* 1.25 0.46
SP-B, Surfactant apoprotein B; SP-C, surfactant apoprotein C; PL, phospholipids; R, right donor lung after ischemia; L, transplanted graft (left donor lung).
Concentrations of the hydrophobic surfactant proteins SP-B and SP-C in large surfactant aggregates (in % of phospholipids) for the donor lung and the
native lung in the standard treatment and the surfactant-treated group. Baseline  explanted left recipient lung. The mean  SEM of 6 independent
experiments is given. The 0-hour values of the native lung represent the baseline values (excised lung from the recipient) and the 0 hours of the graft
represent the postischemia values (obtained by bronchoalveolar lavage [BAL] of the nontransplanted lung at the end of the ischemia period).
*P  .05; †P  .01, comparison between treated and untreated organs.
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TABLE 4. Molecular species of phosphatidylcholine
Baseline
0 hours post
ischemia
6 hours post
reperfusion
12 hours post
reperfusion
16:0/16:0 (% of total)
Standard treatment
Donor lung 40.5 2.1 R 29.9 2.9 L 28.4 1.3 L
Native lung 43.3 1.7 37.5 2.3
Surfactant treatment
Donor lung 40.9 1.4 R 30.1 1.6 L 29.4 1.7 L
Native lung 44.5 5.2
16:0/16:0 PC (total, g/mL)
Standard treatment
Donor lung 92.8 14.2 R 22.6 10.9 L 40.6 6.0 L
Native lung 58.1 8.1 49.8 14.8
Surfactant treatment
Donor lung 78.6 17.5 R 113.9 22.4 L† 219.7 65.5 L*
Native lung 62.3 15.2
16:0/16:1 (% of total)
Standard treatment
Donor lung 12.8 0.8 R 9.9 1.3 L 10.9 0.7 L
Nativelung 12.8 0.5 12.1 0.4
Surfactant treatment
Donor lung 8.2 1.0 R* 10.9 1.7 L 10.4 1.0 L
Native lung 11.3 2.4
16:0/18:1 (% of total)
Standard treatment
Donor lung 6.5 0.2 R 12.5 3.0 L 8.2 0.8 L
Native lung 6.3 0.3 6.3 0.5
Surfactant treatment
Donor lung 8.1 0.9 R 22.4 4.5 L 18.1 3.8 L†
Native lung 6.0 1.4
16:0/18:2 (% of total)
Standard treatment
Donor lung 4.7 0.5 R 6.2 0.7 L 6.0 0.5 L
Native lung 4.5 0.5 4.8 0.4
Surfactant treatment
Donor lung 4.2 0.8 R 5.9 0.6 L 5.3 0.3 L
Native lung 4.1 0.7
16:0/trans 18:1 (% of total)
Standard treatment
Donor lung 10.8 0.5 R 10.4 3.0 L 16.7 1.1 L
Native lung 10.4 0.5 12.9 1.5
Surfactant treatment
Donor lung 12.2 0.8 R 8.6 2.6 L 7.2 1.8 L*
Native lung 11.1 0.9
16:0/14:0 (% of total)
Standard treatment
Donor lung 9.2 0.5 R 7.3 0.6 L 7.5 0.5 L
Native lung 9.4 0.3 8.5 0.3
Surfactant treatment
Donor lung 8.5 0.3 R 7.7 0.8 L 9.1 1.7 L
Native lung 9.1 0.3
14:0, Myristic acid; 16:0, palmitic acid; 16:1, palmitoleic acid; 18:1, oleic acid; trans18:1, elaidic acid; 18:2, linoleic acid. R, right donor lung after ischemia;
L, transplanted graft (left donor lung). Given are the relative (in % of all molecular species) or the absolute (in g/mL BAL) concentration of major PC
molecular species of the donor lung and the native lung in the standard treatment and the surfactant-treated group. Baseline  explanted left recipient
lung. Mean SEM of 6 independent experiments is given. For reasons of complexity of the molecular species analysis, no measurements were undertaken
for 6-hour reperfusion in the native lung (surfactant and standard treatment) and 12-hour reperfusion (surfactant treatment).
*P  .01, †P  .05, comparison between untreated and treated organs.
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Figure 2. Minimum surface tension of large surfactant aggregates in absence (left panel) and in presence of
proteins (right panel) from treated and untreated grafts and native lungs during reperfusion over 12 hours. Depicted
are the mean  SEM of 6 independent experiments. Reconstitution with bronchoalveolar lavage– derived proteins
was performed as detailed in the Methods section. Surface activity was assessed in the Pulsating Bubble
Surfactometer at 2 mg/mL phospholipid always. *P < .05, ***P < .001, comparison between untreated and treated
organs; P < .01), P < .001, comparison between baseline and the untreated donor lung. The 0-hour values
of the native lung represent the baseline values (excised lung from the recipient) and the 0-hour values of the graft
represent the postischemia values (obtained by BAL of the nontransplanted lung at the end of the ischemia period).
Figure 3. Correlation of all data sets of relative palmitic acid concentration in PC and minimum surface tension,
as assessed in the non–surfactant-treated lungs.
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transplanted lungs, by measuring a variety of most relevant
surfactant components hitherto unanalyzed in reperfused
organs. The following mechanisms underlying the impaired
surfactant function were identified:
1. Decrease in the large surfactant aggregate fraction. As
shown in pulse chase studies,23 the alveolar surfactant
pool is composed of two major subfractions, LSA and
the small surfactant aggregates (SSA), with the LSA
representing the highly surface active precursor frac-
tion of the interfacial surfactant film24 and the SSA
representing the much less surface active “degradation
products.”25,26 During reperfusion, a marked decrease
of LSA was noted in the graft, nicely fitting observa-
tions in previous studies.10,13,14,27,28 However, in
some of these studies a corresponding decline in the
LSA fraction was similarly observed in the native lung
of the recipient, which was not the case in the current
investigation. The underlying reason for this differ-
ence may be the fact that separate, synchronized ven-
tilation of each lung was performed, thus avoiding
overinflation of the native lung due to the decreasing
compliance of the transplanted organ. It is in accor-
dance with such reasoning that recent studies provided
direct evidence for accelerated conversion of LSA to
SSA in vivo under conditions of high tidal volume
ventilation strategies.29 However, it may not be de-
duced from the present findings whether the decrease
of LSA in the transplanted lungs was due to reduced
surfactant synthesis in the type II pneumocytes or due
to enhanced breakdown of this surface active fraction
(eg, by proteolytic attack).
2. Altered surfactant composition. The biochemical al-
terations of the surfactant material retrieved from the
graft after 6 and 12 hours of reperfusion included an
impressive decline of the hydrophobic apoproteins
SP-B and SP-C in the LSA fraction, an altered phos-
pholipid profile with decreased percentages of phos-
phatidylglycerol and increased percentages of phos-
phatidylinositol and sphingomyelin, a pronounced
reduction of the degree of palmitoylation of PC, and,
even more prominent, a decrease of DPPC within the
molecular species of PC. Only some of these vari-
ables, all of them being relevant for surfactant func-
tion, have previously been addressed in lung ischemia-
reperfusion studies,12,13,28 and again changes were
then encountered both in the graft and the native lung
under conditions of combined mechanical ventilation,
whereas the biochemical alterations were largely re-
stricted to the transplanted lung in the present inves-
tigation. Overall, the profile of biochemical surfactant
changes is reminiscent of “immature” surfactant in
preterm infants, which may suggest but does not def-
initely prove loss of metabolic capacity of the post-
ischemic type II pneumocytes. The relevance of the
biochemical surfactant alterations for the noted distur-
bances in surfactant function is underscored by the
fact that surface activity and the degree of palmitoyl-
ation of PC were found to be significantly correlated
(Figure 3), as were relative DPPC, SP-B, and SP-C
levels and surface tension lowering properties (data
not shown).
3. Inhibition of surfactant function by proteins. As pre-
viously shown in ARDS patients,4 inhibition of sur-
factant function by BALF-derived proteins was di-
rectly demonstrated by reconstitution of LSA with the
proteins of the individual BALF supernatant, at the
same ratio as observed in the original BALF. Under
these conditions, the surface tension properties further
deteriorated, both regarding minimum surface tension
and adsorption facilities. Thus, protein inhibition is
apparently a potent surfactant inhibitory mechanism in
lungs undergoing ischemia-reperfusion injury. Inter-
estingly, increased minimum surface tension values
have recently also been described for clinically
asymptomatic lung transplant recipients in the further
time course after transplantation, suggesting a persist-
ing disturbance of the alveolar surface tension
regulation.30
The endobronchial administration of 50 mg/kg BW of
Alveofact, an organic solvent extract with excellent surface
activity when tested in vitro or in animal studies, into the
donor lung prior to ischemia, followed by another 200
mg/kg BW being bronchoscopically distributed in both
lungs after reperfusion onset, resulted in a significant im-
provement of arterial oxygenation (see companion
article15a). The present study demonstrates that this is par-
alleled by an impressive restoration of surfactant properties,
with respect to both the biochemical and the biophysical
variables. In parallel to a marked increase in total BALF
phospholipid content, reflecting the alveolar deposition of
the exogenous surfactant, a normalization of the phospho-
lipid/protein ratio and the relative amount of LSA was
noted, and the fatty acid profiles, the molecular species
pattern, and the percentages of the hydrophobic apoproteins
in the LSA fraction in the lungs post–surfactant administra-
tion approached those measured in the exogenous surfactant
material (especially in view of the low percentage of DPPC
in Alveofact (33%; own unpublished observations),
which reflects the overall low abundance of this molecular
species in calf lung surfactant.31
The surface activity was largely improved but not fully
normalized in the presence of the surfactant inhibitory pro-
teins originating from the individual lavage sample. Despite
the fact that a marked improvement of surfactant properties
was achieved by the surfactant replacement regimen, two
aspects deserve particular consideration:
General Thoracic Surgery Gu¨nther et al
352 The Journal of Thoracic and Cardiovascular Surgery ● February 2004
G
TS
1. There was a three- to fivefold increase in the lavagable
phospholipid pool in response to surfactant adminis-
tration. However, the amount of administered surfac-
tant material (250 mg/kg BW) surpassed the endoge-
nous surfactant pool (10-15 mg/kg BW) by at least a
factor of 15! In healthy adult rabbits, an alveolar
turnover time of PC of only 5 to 10 hours has previ-
ously been reported32 and, upon intratracheal injection
of labeled surfactant material, the overall loss from the
airspaces and the lung reached 90% and 70%, respec-
tively, after 24 hours.33 Although clearance studies
have not been conducted in lungs undergoing isch-
emia-reperfusion injury, it thus seems reasonable to
assume that a substantial quantity of the exogenously
administered surfactant material was cleared from the
lung within a few hours. It may be speculated that
some of this material may reenter the alveolar com-
partment due to recycling via type II cells, which
might explain the surprising finding that both in the
graft and in the recipient native lungs, the 12-hour
values of total lavagable phospholipids surpassed the
6-hour values.
2. The minimum surface tension values in the presence
of the individual BALF proteins were markedly im-
proved but not fully normalized in the surfactant-
treated grafts, though all investigated biochemical
variables and the phospholipid/protein ratio were in
physiological ranges. A possible explanation for this
finding is the fact that SP-A is lacking in the bovine
surfactant preparation used in this study, and this
hydrophilic apoprotein is known to enhance protein
resistance of natural surfactant preparations.34 In ad-
dition, changes in the neutral lipid profile, which was
not analyzed in this study, might contribute to impair-
ment of surface activity.
In conclusion, severe abnormalities of the alveolar sur-
factant system were noted after single dog lung transplan-
tation. These abnormalities were restricted to the graft with
virtually normal surfactant function in the recipient native
lung under conditions of separate but synchronized ventila-
tion of each lung to attenuate ventilator-induced lung injury.
The surfactant changes in the graft included loss of the
surface active large aggregate fraction, reduction of most
relevant surfactant components within this fraction (surfac-
tant apoproteins [SP]-B and SP-C, dipalmitoyl-phosphati-
dylcholine [DPPC], phosphatidylglycerol), and surfactant
inhibition by proteinaceous material. Bronchoscopic surfac-
tant administration fully normalized the biochemical and
largely improved the biophysical surfactant properties,
alongside maintenance of lung gas exchange properties.
Surfactant therapy may thus offer protection against reper-
fusion injury in lung transplantation.
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